Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

BACKGROUND: In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival. METHODS: In this random...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Main Authors: Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L, Kay, Edward, Mitchell, Jenna K, Madi, Ayman, Jasani, Bharat, James, Michelle D, Bridgewater, John, Kennedy, M John, Claes, Bart, Lambrechts, Diether, Kaplan, Richard, Cheadle, Jeremy P
Format: Artigo
Sprog:Inglês
Udgivet: Lancet Publishing Group 2011
Fag:
Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3159415/
https://ncbi.nlm.nih.gov/pubmed/21641636
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)60613-2
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker